Literature DB >> 9742557

Development of a highly efficient purification process for recombinant adenoviral vectors for oral gene delivery.

M A Croyle1, D J Anderson, B J Roessler, G L Amidon.   

Abstract

Recently, replication-deficient adenoviruses have received increasing attention as vector for gene delivery and as potential vaccine carriers. With the increased use of the vector in vivo and in clinical trails, the demand for a safe, rapid, and cost effective purification process has been heightened. In this report, a simple and efficient method for the purification of large quantities of live adenoviral vectors was developed. The process involved the replacement of cesium chloride (CsCl) gradients with sucrose gradients. Ultracentrifugation times were reduced and the desalting step eliminated, decreasing total preparation time by 15 hr. A 20-80% linear sucrose gradient provided optimal recovery of infectious viral particles and positioning of the viral band in the gradient. Purification with this gradient system produced a preparation containing 1.39 x 10(14) lac-forming units (lfu)/ml. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis revealed that the process also removed all associated cellular proteins from the preparation. Studies have shown that direct lyophilization of the vector in sucrose after purification produces a product containing 1.4 x 10(12) lfu/ml. Minimal degradation was seen in the lyophilized preparation. A viral concentration of 6 x 10(11) lfu/ml was detected in the product after 150 days in storage at -20 degrees C. This approach will not only simplify the preparation of adenoviral vectors for in vivo studies and clinical trials, but will facilitate production of stable adenoviral formulations for oral gene delivery.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9742557     DOI: 10.3109/10837459809009864

Source DB:  PubMed          Journal:  Pharm Dev Technol        ISSN: 1083-7450            Impact factor:   3.133


  6 in total

1.  Adenoviral transduction of enterocytes and M-cells using in vitro models based on Caco-2 cells: the coxsackievirus and adenovirus receptor (CAR) mediates both apical and basolateral transduction.

Authors:  Filippos Kesisoglou; Phyllissa Schmiedlin-Ren; David Fleisher; Ellen M Zimmermann
Journal:  Mol Pharm       Date:  2010-06-07       Impact factor: 4.939

2.  Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines.

Authors:  Z Shi; M Zeng; G Yang; F Siegel; L J Cain; K R van Kampen; C A Elmets; D C Tang
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

Review 3.  Production of adenovirus vectors and their use as a delivery system for influenza vaccines.

Authors:  Sai V Vemula; Suresh K Mittal
Journal:  Expert Opin Biol Ther       Date:  2010-10       Impact factor: 4.388

4.  Controlled inactivation of recombinant viruses with vitamin B2.

Authors:  Shellie M Callahan; Piyanuch Wonganan; Linda J Obenauer-Kutner; Suganto Sutjipto; Joseph D Dekker; Maria A Croyle
Journal:  J Virol Methods       Date:  2007-12-21       Impact factor: 2.014

5.  Integrin β3 is required in infection and proliferation of classical swine fever virus.

Authors:  Weiwei Li; Gang Wang; Wulong Liang; Kai Kang; Kangkang Guo; Yanming Zhang
Journal:  PLoS One       Date:  2014-10-23       Impact factor: 3.240

Review 6.  Current and emerging cell culture manufacturing technologies for influenza vaccines.

Authors:  Ernest Milián; Amine A Kamen
Journal:  Biomed Res Int       Date:  2015-03-01       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.